Grants and Contributions:
Title:
H5N1 -mRNA vaccine for Highly Pathogenic Avian Influenza for Protection of Canadian Livestock
Agreement Number:
1028947
Agreement Value:
$1,783,815.00
Agreement Date:
Jun 1, 2024 - Mar 4, 2026
Description:
This proposal aims to develop a made-in-Canada solution to the threat posed by Highly Pathogenic Avian Influenza (HPAI) to Canadian livestock. Providence Therapeutics will initiate work to design and develop an mRNA vaccine drug candidate for a relevant strain using their mRNA and INTENT lipid nanoparticle (LNP) platforms.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T2J 3J1
Reference Number:
172-2024-2025-Q4-1028947
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
738045079
Recipient Type:
For-profit organization
Recipient's Legal Name:
Providence Therapeutics Holdings Inc.
Federal Riding Name:
Calgary Midnapore
Federal Riding Number:
48008
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254